JP2019142964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142964A5 JP2019142964A5 JP2019088480A JP2019088480A JP2019142964A5 JP 2019142964 A5 JP2019142964 A5 JP 2019142964A5 JP 2019088480 A JP2019088480 A JP 2019088480A JP 2019088480 A JP2019088480 A JP 2019088480A JP 2019142964 A5 JP2019142964 A5 JP 2019142964A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- group
- section
- epinephrine
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 7
- 229930182837 (R)-adrenaline Natural products 0.000 claims 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- 230000003444 anaesthetic effect Effects 0.000 claims 6
- 239000002738 chelating agent Substances 0.000 claims 6
- 229960005139 epinephrine Drugs 0.000 claims 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- 239000002184 metal Substances 0.000 claims 6
- 229960001484 edetic acid Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims 4
- 229960003655 bromfenac Drugs 0.000 claims 4
- 229960001259 diclofenac Drugs 0.000 claims 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 4
- 229960002390 flurbiprofen Drugs 0.000 claims 4
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 4
- 229960000991 ketoprofen Drugs 0.000 claims 4
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 4
- 229960004752 ketorolac Drugs 0.000 claims 4
- 108010024636 Glutathione Proteins 0.000 claims 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 3
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 3
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims 3
- 229930003427 Vitamin E Natural products 0.000 claims 3
- 229960004308 acetylcysteine Drugs 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 3
- 229960005070 ascorbic acid Drugs 0.000 claims 3
- 235000010323 ascorbic acid Nutrition 0.000 claims 3
- 239000011668 ascorbic acid Substances 0.000 claims 3
- 239000003855 balanced salt solution Substances 0.000 claims 3
- 229960003072 epinephrine hydrochloride Drugs 0.000 claims 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- 235000003969 glutathione Nutrition 0.000 claims 3
- 229960004194 lidocaine Drugs 0.000 claims 3
- 229960001802 phenylephrine Drugs 0.000 claims 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 3
- 229960004919 procaine Drugs 0.000 claims 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 3
- 229960003981 proparacaine Drugs 0.000 claims 3
- 229960002372 tetracaine Drugs 0.000 claims 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 3
- 229960004791 tropicamide Drugs 0.000 claims 3
- 229940046009 vitamin E Drugs 0.000 claims 3
- 235000019165 vitamin E Nutrition 0.000 claims 3
- 239000011709 vitamin E Substances 0.000 claims 3
- 239000008223 sterile water Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886269P | 2013-10-03 | 2013-10-03 | |
| US61/886,269 | 2013-10-03 | ||
| US201361892872P | 2013-10-18 | 2013-10-18 | |
| US61/892,872 | 2013-10-18 | ||
| US201461947778P | 2014-03-04 | 2014-03-04 | |
| US61/947,778 | 2014-03-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546889A Division JP2016532723A (ja) | 2013-10-03 | 2014-10-03 | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142964A JP2019142964A (ja) | 2019-08-29 |
| JP2019142964A5 true JP2019142964A5 (enExample) | 2020-01-30 |
Family
ID=52779188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546889A Pending JP2016532723A (ja) | 2013-10-03 | 2014-10-03 | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 |
| JP2019088480A Pending JP2019142964A (ja) | 2013-10-03 | 2019-05-08 | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546889A Pending JP2016532723A (ja) | 2013-10-03 | 2014-10-03 | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10993921B2 (enExample) |
| EP (1) | EP3052095A4 (enExample) |
| JP (2) | JP2016532723A (enExample) |
| KR (1) | KR20160070077A (enExample) |
| AU (2) | AU2014329412B2 (enExample) |
| BR (1) | BR112016007328A2 (enExample) |
| CA (1) | CA2925008A1 (enExample) |
| IL (1) | IL244687A0 (enExample) |
| MX (1) | MX2016004257A (enExample) |
| WO (1) | WO2015051264A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12702651B2 (en) | 2013-10-03 | 2026-08-11 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| BR112016007328A2 (pt) * | 2013-10-03 | 2017-08-01 | Imprimis Pharmaceuticals Inc | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
| TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| WO2018039420A1 (en) * | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| EP3687475A4 (en) * | 2017-09-26 | 2021-07-28 | YS Pharmtech | STABILIZATION OF EPINEPHRIN FORMULATIONS |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| CA3093725C (en) | 2018-03-23 | 2021-08-24 | Nevakar Inc. | Epinephrine compositions and containers |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US20230277694A1 (en) * | 2022-03-04 | 2023-09-07 | Harrow Ip, Llc | Ophthalmic dye composition and method for administering same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US4590210A (en) * | 1979-03-09 | 1986-05-20 | Langham Maurice E | Compositions for treatment of ocular hypertension |
| US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| CA2002643A1 (en) * | 1988-11-09 | 1990-05-09 | Maryjane Helenek | Antioxidant-free epinephrine solution for ophthalmic use |
| NL9102148A (nl) * | 1991-12-20 | 1993-07-16 | Dsm Nv | Copolymeer van lacton en carbonaat en werkwijze voor het verkrijgen ervan. |
| WO1994008602A1 (en) * | 1992-10-21 | 1994-04-28 | Alcon Laboratories, Inc. | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery |
| US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
| US5709852A (en) | 1995-12-05 | 1998-01-20 | Basf Corporation | Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends |
| WO1998003641A1 (en) | 1996-07-23 | 1998-01-29 | Crandall Wilson T | Transdermal transport of molecules |
| FR2779061B1 (fr) * | 1998-04-14 | 2004-08-20 | Pharmatop | Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant |
| DE19859427A1 (de) | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
| WO2000048662A1 (en) * | 1999-02-16 | 2000-08-24 | Prismedical Corporation | Single dose delivery device |
| EP1326642A2 (en) * | 2000-09-29 | 2003-07-16 | Board of Trustees operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
| FR2833493B1 (fr) * | 2001-12-18 | 2005-09-23 | Ioltechnologie Production | Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble |
| EP1531794B1 (en) * | 2002-06-28 | 2017-05-10 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
| ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US20050176823A1 (en) | 2004-02-10 | 2005-08-11 | Diaz Robert L. | Intra-operative procedure for post-operative pain control |
| FR2882930B1 (fr) * | 2005-03-09 | 2009-03-27 | Walid Katib | Nouvelles compositions ophtalmologiques et leur mode d'utilisation |
| DE102005038368A1 (de) | 2005-08-13 | 2007-02-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Doppelkammer-Behälter zur Lyophilisation, Verfahren zu dessen Befüllung und dessen Verwendung |
| US20070196324A1 (en) | 2006-02-01 | 2007-08-23 | Keefe Candace R | Cellulite skin treatment methods and compositions |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US20080269347A1 (en) * | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| US20090017120A1 (en) | 2007-03-23 | 2009-01-15 | Humco Holding Group, Inc. | Phase stable lecithin organogel composition |
| US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| EP2711001A3 (en) | 2008-11-14 | 2014-07-02 | Archer-Daniels-Midland Company | Organogel compositions and processes for producing |
| CN101444481A (zh) | 2009-01-06 | 2009-06-03 | 河北科技大学 | 不含抑菌剂的托吡卡胺滴眼液及其制备方法 |
| WO2010139752A2 (en) * | 2009-06-04 | 2010-12-09 | Alk Ag | Stabilised composition comprising at least one adrenergic compound |
| WO2011156803A2 (en) | 2010-06-11 | 2011-12-15 | Transdel Pharmaceuticals, Inc. | Anti-cellulite composition and method of treating cellulite |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| KR20140112825A (ko) | 2013-03-14 | 2014-09-24 | 삼성전자주식회사 | 전자 장치의 전자 결제 방법 및 장치 |
| CA2915814A1 (en) | 2013-06-18 | 2014-12-24 | Harrow Ip, Llc | Local use of pentoxifylline to treat peyronie's disease |
| WO2015006299A1 (en) | 2013-07-08 | 2015-01-15 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical formulations of tranexamic acid and their use |
| BR112016007328A2 (pt) | 2013-10-03 | 2017-08-01 | Imprimis Pharmaceuticals Inc | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
| WO2018039420A1 (en) | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
-
2014
- 2014-10-03 BR BR112016007328A patent/BR112016007328A2/pt not_active IP Right Cessation
- 2014-10-03 US US14/506,120 patent/US10993921B2/en active Active
- 2014-10-03 JP JP2016546889A patent/JP2016532723A/ja active Pending
- 2014-10-03 AU AU2014329412A patent/AU2014329412B2/en active Active
- 2014-10-03 CA CA2925008A patent/CA2925008A1/en not_active Abandoned
- 2014-10-03 KR KR1020167009782A patent/KR20160070077A/ko not_active Ceased
- 2014-10-03 WO PCT/US2014/059077 patent/WO2015051264A1/en not_active Ceased
- 2014-10-03 EP EP14851190.0A patent/EP3052095A4/en not_active Withdrawn
- 2014-10-03 MX MX2016004257A patent/MX2016004257A/es unknown
-
2016
- 2016-03-21 IL IL244687A patent/IL244687A0/en unknown
- 2016-08-19 US US15/241,958 patent/US20160354308A1/en not_active Abandoned
- 2016-08-25 US US15/247,524 patent/US11045432B2/en active Active
-
2019
- 2019-05-08 JP JP2019088480A patent/JP2019142964A/ja active Pending
-
2020
- 2020-05-08 AU AU2020203044A patent/AU2020203044A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,023 patent/US20210275471A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010090142A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2012520883A5 (enExample) | ||
| WO2007056232B1 (en) | Methods of using saha and bortezomib for treating cancer | |
| RU2009131065A (ru) | Новая композиция для лечения метаболического синдрома | |
| WO2010106083A1 (en) | Combination therapies for treating metabolic disorders | |
| RU2009118960A (ru) | Комбинации ацетаминофена/ибуппрофена | |
| JP2005518361A5 (enExample) | ||
| CA2671904A1 (en) | Intermediate duration neuromuscular blocking agents and antagonists thereof | |
| JP2010265321A5 (enExample) | ||
| JP2004538303A5 (enExample) | ||
| IL194885A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid | |
| JP2009538276A5 (enExample) | ||
| ECSP066535A (es) | Composiciones y formas de dosis para absorcion mejorada de gabapentina y pregabalina | |
| JP2009517473A5 (enExample) | ||
| JP2009535370A5 (enExample) | ||
| RU2011109884A (ru) | Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| PT1143958E (pt) | Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação. | |
| JP2019501226A5 (enExample) | ||
| JP2019529541A5 (enExample) | ||
| JP2004532828A5 (enExample) | ||
| RU2018128793A (ru) | Способы и составы для лечения и/или защиты от острой печеночной недостаточности и других гепатотоксических состояний | |
| KR890006228A (ko) | 항종양제로서 폴리아민 유도체 | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы |